Human Lung Mast Cell Products Regulate Airway Smooth Muscle CXCL10 Levels

H. Alkhouri, V. Cha, K. Tong, L. M. Moir, C. L. Armour, and J. M. Hughes

1 Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia
2 Discipline of Pharmacology and Woolcock Institute of Medical Research, The University of Sydney, Sydney, NSW 2006, Australia

Correspondence should be addressed to J. M. Hughes; margaret.hughes@sydney.edu.au

Received 21 July 2013; Accepted 23 December 2013; Published 6 February 2014

1. Introduction

In asthma, the airway smooth muscle (ASM) cells may play a significant role in supporting inflammation locally. They produce a wide range of chemokines and growth factors in vitro in response to proinflammatory cytokines, which are elevated in asthma following release by activated inflammatory cells and other airway structural cells [1–3].

Degranulating mast cells (MC) are present in higher numbers in the ASM bundles of people with asthma than people without asthma [4–7]. MC numbers are further increased in allergic compared with nonallergic asthma [5] and thus may be a specific feature of eosinophilic asthma. There is conflicting evidence about the presence of MC in the ASM in severe asthma, which is often associated with neutrophilia and steroid resistance. Carroll et al. [4] found that degranulating MC numbers were highest in the ASM layer in fatal asthma, whereas Balzar et al. [8] found no evidence of them in the ASM in biopsies from a severe asthma cohort.

MC activation by allergen mediated cross-linking of IgE results in the release of a variety of preformed and newly synthesised mediators [9, 10]. These include the major granule-derived mediators histamine and tryptase and newly synthesised cysteinyl leukotrienes, whose effects on ASM contractility are well established. MC also produce other proteases, arachidonic acid metabolites, and a wide range of cytokines and growth factors [9, 10]. The relative balance of these mediators in the vicinity of the ASM cell will determine the overall effect MC have on ASM production of a certain chemokine. What role that chemokine plays in airway inflammation will depend on its quantity and activity locally.

To date, the effects of many MC products on ASM chemokine production are unknown. When studied individually, some MC mediators directly affect ASM chemokine production and thus may regulate inflammation locally. For example, interleukin (IL-)1β or tumour necrosis factor (TNF-)α alone [11] and IL-4 or IL-13 alone and in combination with IL-1β [12], induce ASM release of the potent eosinophil...
chemoattractant CCL11 (eotaxin), while we and others have shown that MC proteases cleave CCL11 [13, 14]. We have also shown that histamine enhances IL-1β-induced granulocyte-macrophage colony stimulating factor (GM-CSF) release but strongly inhibits CCL5 (RANTES) release by ASM cells from people with and without asthma [15]. Further studies are needed to investigate the pro- and anti-inflammatory effects of MC and whether or not they can regulate their own recruitment to the ASM and survival there.

Increased localization of MC to the ASM layer could be controlled by many ASM cell derived chemokines, as human lung MC (HLMC) express a range of chemokine receptors [16]. However MC in the ASM of people with asthma are CXCR3 positive, whereas less than half of the MC elsewhere in the airway submucosa express CXCR3. Further, ASM in biopsies from people with asthma are often (~50%) immunoreactive for the CXCR3 ligand CXCL10, whereas the ASM in biopsies from people without asthma are not [17]. In vitro we have established that asthmatic ASM cells produce CXCL10 more rapidly than nonasthmatic ASM cells under Th1 inflammatory conditions [18] and MC chemotaxis towards medium from the asthmatic ASM cells is driven by CXCL10 activating CXCR3 on the MC [17]. Whether or not MC can regulate ASM CXCL10 production and activity is not known.

Thus, the aims of this study were to investigate the effects of MC products on CXCL10 production by ASM cells from people with and without asthma. The effects of the granule-derived products histamine and tryptase, as well as the overall effects of human lung MC products released in the first 2 h or 2–24 h after activation, on ASM CXCL10 production were examined.

2. Methods

2.1. Agents. Recombinant Human IFNγ (BD Biosciences, Australia), IL-1β, and TNFα (R&D Systems, Minneapolis, MN) were reconstituted in sterile PBS containing 0.1% bovine serum albumin (BSA). Histamine, chlorpheniramine, and ranitidine (Sigma-Aldrich, Sydney, Australia) were reconstituted in water for irrigation (Baxter, Sydney, Australia). Human lung tryptase (≥5,000 mU/mg/mL of vehicle consisting of 1 M NaCl, 50 mM sodium acetate, 0.01% sodium azide, and 50 μM heparin) was obtained from Calbiochem (La Jolla, CA, USA). BSA and leupeptin were purchased from Sigma-Aldrich. All agents were stored in aliquots at −20°C, except for IFNγ which was stored at −80°C.

2.2. Airway Smooth Muscle. ASM cell cultures were established from lung samples donated by 16 people with asthma (mean age 36 y and range 23–62 y) and 17 people without asthma (mean age 55 y and range 29–83 y). The lung samples were either bronchial biopsies or resected lung tissue obtained from people undergoing surgery for thoracic malignancies or lung transplantation. All samples were obtained with the donor’s informed consent and approval from Sydney South West Area Health Service or Australian Red Cross. Approval for this study was granted by The University of Sydney Human Ethics Committee.

2.3. Airway Smooth Muscle Cell Culture. ASM bundles were dissected out from macroscopically normal lung samples and grown as explants. The cells from people who had no doctor diagnosis of asthma are referred to as nonasthmatic. ASM cells were maintained in culture as previously described [19] in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich) supplemented with 10% v/v heat-inactivated foetal bovine serum (FBS), 100 units/mL penicillin G, 100 μg/mL streptomycin sulphate, 25 μg/mL amphotericin B, 4 mM L-glutamine, and 20 mM HEPES, at pH 7.4 (growth medium) and grown at 37°C in a humidified 5% CO2 in air atmosphere. The cells adopted a "hill and valley" growth pattern and were positive for α-smooth muscle actin and h-calponin using immunofluorescence [19, 20]. ASM cells harvested between passages 4 and 7 were used in experiments.

2.4. Histamine and Tryptase Effects on ASM Cell CXCL10 Production. To investigate the effects of histamine and tryptase on ASM cell CXCL10 production, ASM cells were seeded into the wells of 6- or 24-well plates at 1 × 10^4 cells/cm^2 in growth medium. After 7 days growth, the cells were serum-deprived for 48 h in FBS-free DMEM supplemented as described above and also with 0.1% v/v bovine serum albumin (BSA) (serum-free medium). The well cultures were left untreated or treated with histamine (1, 10, or 100 μM), tryptase (0.2, 1.0, or 5.0 nM), or the vehicle for tryptase and heparin (50 μM), as used previously [15]. Immediately afterwards the cytokines IL-1β, TNF-α, and IFNγ, alone and in combination (cytomix), were added to untreated and treated wells. The cytokines were each used at 10 ng/mL and all treatments were performed in duplicate.

To investigate which histamine receptor was involved in the effects of histamine on ASM cell CXCL10 release, the cells were treated in duplicate with either the H1 receptor antagonist chlorpheniramine at 1 μM [15, 21] or the H2 receptor antagonist ranitidine at 50 μM [15, 22], for 30 minutes prior to the addition of histamine followed by the cytokines.

To investigate whether the proteolytic activity of tryptase was involved in its effects on ASM cell CXCL10 release, an aliquot of the same tryptase batch was first heat-inactivated at 56°C for 30 minutes and then immediately added to the ASM cells, or the serine protease inhibitor leupeptin (50 μM) [15] was added to tryptase-treated ASM cells 3 h after the addition of the cytokines.

After 4 hours cytokine stimulation, the cells in the well cultures were washed and total RNA was extracted using the guanidine thiocyanate/phenol chloroform method [23]. The RNA was reverse transcribed using RevertAid First Strand cDNA Synthesis Kit (Fermentas Life Sciences, Hanover, MD, USA) and the cDNA amplified by PCR using FAM-labeled human CXCL10 and VIC labeled 18sRNA TaqMan probes on an ABI Prism 7500 (Applied Biosystems) as described previously [18].
Alternatively, the ASM well cultures were incubated with the cytokines for 24 hours and then the culture medium (CM) was collected and stored at −20 °C for later analysis of CXCL10 levels using the CXCL10 Duo-set ELISA kit and protocol (R&D Systems, Minneapolis, MN, USA).

2.5. Tryptase Effects on Recombinant Human CXCL10. To investigate whether tryptase can cleave CXCL10, recombinant human CXCL10 diluted in serum-free medium to 250, 500, and 1000 pg/mL, or the same volume of CM from cytokine-stimulated ASM cells, was added to a series of wells in microwell plates. Tryptase (1 nM), heat-inactivated tryp fate or tryp fate followed by leupeptin (50 μM) 3 hours later, was added to duplicate wells containing CXCL10 or the ASM cell CM and the plates were incubated at 37 °C for 24 hours and then CXCL10 was detected using ELISA.

2.6. Human Lung Mast Cell Isolation and Activation. MC were isolated from macroscopically normal lung tissue dissected immediately by a pathologist from lung samples donated by 6 people undergoing surgery for thoracic malignancies. The MC were isolated within 24 hours of resection as previously described [14, 24]. Briefly, the lung parenchyma was chopped finely, washed, and digested with collagenase (7.5 mg/g tissue) and hyaluronidase (3.75 mg/g tissue) for 90 minutes at 37°C. MC in the cell suspension were positively selected using sheep anti-mouse IgG-coated magnetic beads (Dynal, Oslo, Norway), which were coated with a second anti-human CD117 (clone YB588; Bioscientific, Sydney, Australia) antibody (5 μg/mL) just before use and resuspended at 1 × 10⁶ cells/mL in growth medium. The HLMC were activated with IgE (2.5 μg/mL) and goat anti-human IgE (1 μg/mL) (Calbiochem, CA, USA) immediately or left unstimulated. The HLMC culture supernatants (SN) were collected after 2 hours (MC 2 h SN) and fresh growth medium was added to the HLMC. This medium was collected 24 hours after the HLMC were first activated (MC 24 h SN). The MC 2 h and 24 h SN were stored at −20°C until immediately before use in the experiments described below.

2.7. ASM Cell Treatment with Human Lung Mast Cell Products. To investigate the effects of HLMC products released at different times after activation on ASM cell CXCL10 production, harvested ASM cells were placed in the wells of 96-well plates at a density of 3200 cells/100 μL/well in growth medium and incubated as described above. After 24 hours the cells were serum-deprived in serum-free medium for 72 hours. Then the ASM cells were stimulated with growth medium ± IFNγ (10 ng/mL) and, after 30 minutes, treated in triplicate or quadruplicate with the MC 2 h or 24 h SN (prepared as described above) at 0, 20, or 40% v/v in growth medium in the presence of the same concentration of IFNγ, or left untreated. This order was used to ensure that the ASM cells were activated by IFNγ as it induces CXCL10 production and the effects of the MC SN directly on its activity were not known. After 48 hours of treatment, the medium was collected from each ASM culture and stored at −20°C for later measurement of CXCL10 levels using ELISA. ASM cell CXCL10 release in response to growth medium ± IgE/anti IgE was also determined.

2.8. Protease Involvement in the Effects of HLMC Products Released by 2 h. To establish whether or not MC proteases were involved in modulating ASM CXCL10 release, 2 h MC SN or the same SN already pretreated for 30 minutes with 50 μM leupeptin were added at 40% v/v in growth medium to the ASM cell well cultures. After 3 hours coincubation at 37°C, leupeptin was added to some of the wells containing untreated MC SN and the incubation was continued. All the culture medium was collected from each well after 48 hours and CXCL10 levels were quantified using ELISA.

To investigate if the effects of 24 h MC SN on cytokine-induced ASM CXCL10 could be due to TNF-α produced by MC, TNF-α levels were measured in the MC SN using ELISA. Then serum-deprived ASM cells were stimulated with IFN-γ (10 ng/mL), with and without a similar range of TNF-α concentrations to those detected in the MC SN, and made up in growth medium. After 24 h incubation at 37°C, the culture SN were collected and CXCL10 levels in them were quantified as above.

The effects of 2 h MC SN, β-tryptase, or leupeptin on the CXCL10 ELISA capture antibody were also investigated. Wells were coated with CXCL10 capture antibody and washed ready for use as usual; then either 40% v/v 2 h MC SN, 1 mM β-tryptase, 50 μM leupeptin, or vehicle, in growth medium or growth medium alone, was added to the wells already containing capture antibody. After incubation together for 1 hour at 37°C, the wells were washed and doubling dilutions of CXCL10 standards were added and the remainder of the ELISA protocol was completed without modification.

2.9. Data Analysis. CXCL10 mRNA or protein levels from replicate treatments were averaged. The results for each experiment were expressed as a percentage of the cytokine control. The mean ± SEM was then calculated for the asthmatic and non-asthmatic cell lines and for each treatment. Statistical analyses were performed on all data using Statview (SAS Institute, Cary, North Carolina) or Prism 5.03 (GraphPad, La Jolla, CA) and significance (P < 0.05) was determined using 1-way or 2-way analysis of variance (ANOVA) with the Bonferroni correction for multiple comparisons or using the Student’s t-test as appropriate.

3. Results

3.1. Histamine Effects on ASM Cell CXCL10 Production. In preliminary experiments we established that histamine did not induce ASM cell CXCL10 release. The levels of CXCL10 released by untreated ASM cells from people with and without asthma were very low (Table 1). Histamine treatment at 1,10, or 100 μM for 24 h did not alter CXCL10 release by the ASM cells (data not shown).

Similar to previous reports, cytokine stimulation increased ASM cell CXCL10 production. IL-1β, TNF-α and IFNγ, alone and in combination (cytomix), stimulated
significant CXCL10 release from the asthmatic and non-asthmatic ASM cells (Table 1).

Histamine had much greater inhibitory effects on IL-1β- and TNF-α-induced CXCL10 release than cytokin-induced release from both asthmatic and non-asthmatic ASM cells. The inhibitory effects of 1, 10, and 100 μM histamine on IL-1β-, and TNF-α-induced CXCL10 were all significant and concentration-related (Figures 1(a) and 1(b)). Histamine at the highest concentration (100 μM) reduced IL-1β-induced release from asthmatic (n = 3, P < 0.0001) and non-asthmatic (n = 4, P < 0.0001) ASM cells to a similar extent (35.7 ± 3.3% and 37.5 ± 6.5% of the IL-1β control, resp.) (Figure 1(a)). Whereas it reduced TNF-α-induced release from asthmatic (n = 3, P < 0.0001) and non-asthmatic (n = 4, P = 0.0013) ASM cells down to 39.6 ± 3.7% and 61.0 ± 7.9% of the TNF-α control, respectively, (Figure 1(b)), but this difference in effects on asthmatic and non-asthmatic cells did not achieve statistical significance. In contrast, histamine had no effect on IFNγ-induced CXCL10 release from asthmatic and non-asthmatic ASM cells (Figure 1(c)) but at each concentration did reduce cytokin-induced release from non-asthmatic cells very slightly (Figure 1(d)).

Although IL-1β and TNF-α both induced significant increases in CXCL10 gene expression over 4 hours, histamine 10 μM did not affect CXCL10 mRNA levels induced by either cytokine (Figure 2(a)), even though it significantly reduced CXCL10 release. Further, the effects of 10 μM histamine on CXCL10 release were not reversed by pretreating the asthmatic and non-asthmatic ASM cells with the H1 and H2 receptor antagonists chlorpheniramine and ranitidine, respectively, or with the cell membrane permeable adenylate cyclase inhibitor SQ 22,536 (Figures 2(b) and 2(c)).

3.2. Tryptase Effects on ASM Cell CXCL10 Production. Neither tryptase (0.2, 1, or 5 nM) nor the vehicle (heparin 50 μM) induced CXCL10 release from ASM cells from people with and without asthma. The levels of CXCL10 were similar to those in the untreated controls (asthmatic: 0.15 ± 0.06 ng/mL, n = 3; non-asthmatic: 0.15 ± 0.07 ng/mL, n = 4).

Tryptase reduced the levels of CXCL10 detected in CM from asthmatic and non-asthmatic ASM cells. When tryptase (1 nM) was added to the ASM cells 30 minutes after the

| Cytokine | Asthmatic CXCL10 Release (ng/mL, mean ± SEM) | Non-asthmatic CXCL10 Release (ng/mL, mean ± SEM) |
|----------|---------------------------------------------|--------------------------------------------------|
| Treatment | (n = 5)                                      | (n = 5)                                          |
| Unstimulated | 0.16 ± 0.04                                 | 0.10 ± 0.03                                      |
| IL-1β      | 1.34 ± 0.27*                                | 7.35 ± 3.53*                                     |
| TNF-α      | 6.45 ± 1.56*                                | 20.71 ± 9.44*                                    |
| IFNγ       | 17.06 ± 11.57*                              | 13.27 ± 10.0*                                    |
| Cytomix    | 49.57 ± 16.21**                             | 66.56 ± 14.44**                                  |

*Except where indicated; **P ≤ 0.01 and ***P < 0.001 compared to unstimulated, paired t-test.

3.3. Tryptase Effects on Recombinant Human CXCL10. The proteolytic effects of tryptase on CXCL10 were investigated further in a cell-free system. Significantly less CXCL10 was detected in wells containing human recombinant CXCL10 (500–1000 pg/mL in serum-free medium) following treatment for 24 hours at 37°C with 1 nM tryptase than with its vehicle (Figure 4). CXCL10 levels were not reduced in wells treated with heat-inactivated tryptase and were even increased in those treated with trypsin followed by leupeptin (50 μM) 3 hours later. Similarly, tryptase treatment after-collection also markedly reduced detectable CXCL10 levels in culture medium collected from cytokine-stimulated ASM cells when compared to the vehicle-treated controls (data not shown). The capacity of the antibody from the Duo-set kit to capture CXCL10 standards was not affected by direct incubation with tryptase, its vehicle, or leupeptin at the concentrations used above (data not shown).

3.4. Effects of Human Lung Mast Cell Products on ASM Cell CXCL10. Asthmatic and non-asthmatic ASM cells responded in a similar way to the products released by human lung MC, but the effects of the 2 h and 24 h MC SN on ASM cell CXCL10 production differed. Although 10% FBS did not induce ASM cell CXCL10 release, IFNγ induced substantial

| Cytokine | Asthmatic CXCL10 Release (% cytokine control, mean ± SEM) | Non-asthmatic CXCL10 Release (% cytokine control, mean ± SEM) |
|----------|----------------------------------------------------------|---------------------------------------------------------------|
| Stimulus | (n = 4)                                                  | (n = 7)                                                       |
| IL-1β    | 22.8 ± 14.5*                                             | 9.0 ± 3.6*                                                    |
| TNF-α    | 36.3 ± 14.4*                                             | 25.2 ± 5.1*                                                   |
| IFNγ     | 11.1 ± 4.3*                                              | 13.6 ± 3.5*                                                   |
| Cytomix  | 65.8 ± 15.8*                                             | 42.8 ± 9.4*                                                   |

*P < 0.01 compared to cytokine control, paired t-test.
Figure 1: The effects of histamine on CXCL10 production by asthmatic (A) and nonasthmatic (NA) ASM cells. Confluent serum-deprived ASM cells were stimulated with the individual cytokines (a) IL-1β, (b) TNFα, (c) IFNγ, or (d) cytotoxin for 24 h and CXCL10 released into the culture medium quantified using ELISA. *P < 0.05 compared with the cytokine control, ANOVA.

release in its presence over the 48 hour incubation. CXCL10 release was generally greater from asthmatic ASM cells (9.3 ± 2.4 ng/mL, n = 6) than non-asthmatic ASM cells (5.4 ± 2.0 ng/mL, n = 6), but the difference was not statistically significant. ASM cell CXCL10 release was not affected by the presence of IgE/anti-IgE (Figure 5(a)).

The MC 2 h SN markedly reduced asthmatic and non-asthmatic ASM cell CXCL10 levels following IFNγ stimulation. At 20% v/v, the MC 2 h SN significantly reduced non-asthmatic ASM cell CXCL10 levels down to 47 ± 12% of the FBS-IFNγ control and at 40% v/v significantly reduced asthmatic ASM cell CXCL10 levels to 46 ± 15% of control
(Figure 5(b)). To investigate whether this effect was due to MC protease activity affecting early events leading to CXCL10 production or affecting CXCL10 after new gene transcription had commenced, leupeptin (50 μM) was added at two different steps. Leupeptin inhibited the effects of the MC 2 h SN irrespective of whether the SN were treated with it before they were added to the ASM cells (0 h), or it was added to the ASM cultures 3 hours after the SN (3 h) (Figure 5(c)). When the CXCL10 capture antibody was incubated with the MC 2 h SN there was no effect as detection of human recombinant CXCL10 in the ELISA remained the same as with the vehicle-treated and untreated capture antibody controls (data not shown).

In contrast, the MC 24 h SN increased asthmatic and non-asthmatic ASM cell IFNγ-induced CXCL10 release. The MC 24 h SN at 20% and 40% v/v significantly increased IFNγ-induced CXCL10 release from asthmatic cells up to 157 ± 28% and 137 ± 16% and from non-asthmatic cells up to 155 ± 22% and 170 ± 32% of the FBS-INFNγ control, respectively (Figure 6(a)). As TNF-α acts synergistically with IFNγ to increase CXCL10 production, the levels of TNF-α in MC SN were quantified. The MC 2 h and 24 h SN contained TNF-α at 227 ± 79 and 434 ± 87 pg/mL, respectively (Figure 6(b)). TNF-α over those concentrations increased ASM cell IFNγ-induced CXCL10 release by ≥5fold (Figure 6(c)).

4. Discussion

In asthma, the ASM produces the chemokine CXCL10 which we have previously shown induces MC chemotaxis through CXCR3 engagement [17]. CXCL10 may also mediate CXCR3+ T lymphocyte recruitment to the ASM in severe asthma and following allergen challenge [25]. Thus CXCL10 may be critical in asthma because it can induce airway myositis. This is the first study to examine the effects of MC products on CXCL10 production by ASM cells from people with and without asthma. The effects of individual granule-derived MC products and all the products released by human lung MC in the first 2 or 2–24 hours following IgE receptor activation were investigated. The key granule-derived product histamine reduced ASM cell CXCL10 release induced by the proinflammatory cytokines IL-1β and TNF-α. As well, the proteolytic activity of tryptase, or the leupeptin-sensitive serine proteases released by human lung MC within
two hours of activation, markedly reduced CXCL10 levels released following ASM cell cytokine stimulation. In contrast, human lung MC products synthesised and released later increased ASM CXCL10 release and levels of human lung MC-derived TNF-α were sufficient to amplify IFNγ-induced CXCL10 production. These findings are evidence that mast cells are able to regulate ASM cell CXCL10 production and degradation and thus may regulate their own and/or T cell recruitment to the ASM in asthma.

Following MC activation histamine, along with other products also stored in the granules, is released rapidly (reviewed in [10]). Histamine has a very broad spectrum of activities and histamine levels are high in the bronchoalveolar lavage fluid of people with asthma and correlate with airway hyperresponsiveness [26]. The contractile effects of histamine on ASM are well characterised and mediated via its H1 and H2 receptors, which are highly expressed on ASM. Histamine binding to the H1 receptor primarily activates phospholipase C-inositol triphosphate-diaclylglycerol signalling and leads to Ca^{2+} release from intracellular stores and protein kinase C activation, both of which can also upregulate cAMP [27]. Signalling via H2 receptors activates adenylate cyclase to directly generate cyclic adenosine monophosphate (cAMP), but H2 receptors are also coupled to the phosphoinositide system [27]. Through the H1 receptor, histamine can also activate NFkB [28, 29] and thus might be expected to

Figure 3: The proteolytic effects of tryptase on cytokine-induced CXCL10 production by asthmatic (A) and non-asthmatic (NA) ASM cells. Confluent serum-deprived ASM cells were stimulated with (a) IL-1β, (b) TNFα, (c) IFNγ, or (d) cytomicfor 30 minutes prior to and during treatment with tryptase, heat-inactivated tryptase (HI), or its vehicle (veh) for 24 h. Leupeptin (Leu) was added to some cell cultures 3 h after the cytokines. CXCL10 in the culture supernatants was detected using ELISA. *P < 0.05 compared with the vehicle control, ANOVA.
Histamine and cytokines may have opposing effects on intracellular (Ca\(^{2+}\)) levels in human ASM cells. Mitochondria buffer cytosolic (Ca\(^{2+}\)) levels [37] and histamine causes a rapid increase in both cytosolic and mitochondrial (Ca\(^{2+}\)) levels. Whereas TNF-\(\alpha\) decreases mitochondrial (Ca\(^{2+}\)) levels through the mitochondrial Na\(^+\)/Ca\(^{2+}\) exchanger, while increasing cytosolic (Ca\(^{2+}\)) levels [37]. As indicated above, TNF-\(\alpha\) also induces NF\(\kappa\)B mediated CXCL10 gene transcription [18, 32], whereas histamine does not. NF\(\kappa\)B mediated gene transcription is inhibited by SERCA pump inhibition [38], including CXCL10 production, especially in asthmatic ASM cells [35]. If histamine modulated TNF-\(\alpha\)-induced changes in mitochondrial and cytosolic (Ca\(^{2+}\)) levels to limit ASM cell CXCL10 production, reduced CXCL10 mRNA levels in histamine-treated cells would have been observed in this study but they were not.

The lack of effect of the H1 and H2 receptor antagonists was surprising in view of our previous findings. Firstly, chlorpheniramine prevented histamine-induced changes in ASM cell GM-CSF and RANTES release following stimulation by IL-1\(\beta\) or TNF-\(\alpha\) [15]. Secondly, the long acting \(\beta_2\)-adrenoceptor agonist salmeterol which, like histamine, increases cAMP levels also inhibited ASM cell CXCL10 release induced by these cytokines [36]. Further, the effects of histamine appeared to be posttranscriptional, as cytokine-induced CXCL10 gene expression was not affected. Posttranscriptional effects of histamine on keratinocytes have been reported but were mediated via the H1 receptor [39]. To our knowledge, H3 receptors are expressed on cholinergic nerves, but not ASM in the airways [40]. Gantner and colleagues [41] used specific primers for receptors H1-4 and detected mRNA expression for H1, H2, and H4 receptors, but not for H3 receptors. Perhaps the indirect inhibitory effects of histamine observed in this study were mediated via the Gi/o coupled H4 receptors. H4 receptors play an important role in the regulation of immune responses, including chemokine production, in the skin [42] and so might also regulate ASM cell chemokine production. Further studies of cytokine-stimulated ASM cell CXCL10 production in the presence of histamine are needed to determine the molecular mechanisms underlying its effects and histamine receptor involvement. Recently developed selective agonists (e.g., 4-methylhistamine) and antagonists (e.g., JNJ7777120) for H4 receptors would be useful to clarify its role [43].

ASM cells also express the organic cation transporter 3 (OCT3 or EMT) in addition to histamine receptors [44]. Histamine is a good substrate for OCT3 [45] and so it is possible that histamine entered the ASM cells stimulated with IL-1\(\beta\) and TNF-\(\alpha\) via OCT 3 and affected posttranscriptional
events involved in CXCL10 protein synthesis/release. Further studies are needed to investigate the above possibilities and the mechanisms involved in any effects of histamine.

Importantly, this study is the first demonstration that CXCL10 is susceptible to digestion by serine proteases such as tryptase. The levels of CXCL10 released following cytokine stimulation were reduced by tryptase, which is stored in the granules as a tetrameric complex with proteoglycans such as heparin and released at the same time as histamine. Unlike histamine, tryptase reduced detectable CXCL10 levels irrespective of the individual cytokine used to stimulate the ASM cells. This effect was due to tryptase protease activity as it was prevented by heat-inactivation and the serine protease inhibitor leupeptin. Further it was likely due, at least in part, to direct tryptase proteolysis of CXCL10 detected in a cell-free system. In addition, leupeptin added 3h after any of the cytokines, when there is already a substantial increase in CXCL10 mRNA expression [18], completely prevented the reduction in cytokine-induced CXCL10 levels. These findings add CXCL10 to the chemokines CCL11 (eotaxin) and CCL5 (RANTES) that are also produced by ASM cells and cleaved by tryptase in vitro [13] or by ASM cell coculture with MC [46].

Although other studies have investigated the effect of MC products individually on ASM cell synthetic function as above, this is the first study to also examine the overall effects of MC products released at different times after MC activation on asthmatic and non-asthmatic ASM cell CXCL10 production. As ASM cells do not release CXCL10 constitutively, or in response to FBS, IFNγ was used to induce CXCL10 release so the effects of the MC products on it could be assessed. The effects of rapidly released human lung MC products (2h SN) on ASM cell CXCL10 levels complement the effects obtained with tryptase. Early MC products reduced asthmatic and non-asthmatic ASM cell IFNγ-induced CXCL10 levels by a similar amount. These effects were also prevented by leupeptin added later, indicating that serine proteases were involved, but do not affect early CXCL10 gene transcription.

As well, a role for histamine cannot be completely dismissed. MC supernatants generated in the manner used here contain significant amounts of histamine [47], which would have been ineffective against the IFNγ-induced CXCL10 production used in this study. Early release of histamine...
may limit CXCL10 production generated under different inflammatory conditions when IFNγ is absent.

In contrast to the effects of the MC products released early, newly synthesised products released sometime later (24 h SN) increased IFNγ-induced CXCL10 levels. Again the proportional effects of the MC products on ASM cells from people with and without asthma were similar. MC produce TNF-α [48], which synergistically increases IFNγ-induced CXCL10 production by ASM cells in vitro [18, 32, 34]. This study has extended those findings by providing evidence that products released from human lung MC activated by IgE also increase CXCL10 release and include sufficient TNF-α to cause such an increase. Although TNF-α levels in MC SN collected early were half those in the SN collected later, they were still sufficient to amplify IFNγ-induced CXCL10 release. However no increase was observed, probably because the granule-derived proteases present in the SN cleaved the CXCL10 after it was released and thus reduced the amount of protein detected.

In this study, the effects of MC products released together, either early or later, after IgE receptor activation were examined in vitro on ASM cells obtained from people with and
without asthma. The MC could only be isolated from larger lung samples as they became available and were all from people without asthma. The effects of MC from people with asthma on asthmatic ASM cell CXCL10 production may be different. However different percentages of the MC SN were present in the ASM layer in different numbers in asthma [4, 5, 7]. Thus not all ASM cells are in direct contact with a MC, but they have been observed in close proximity to each other [6, 7]. Given this proximity, it is apparent from our study that MC products could still affect ASM chemokine production in the absence of cell-cell contact.

5. Conclusions

This is the first study to examine the effects of MC products on CXCL10 production by ASM cells. Activated MC numbers are increased in the ASM in eosinophilic asthma and T-lymphocytes are present in the ASM in severe asthma and following allergen challenge. ASM-derived CXCL10 production may play a role in the recruitment of these cells to the ASM as both cell types express the CXCL10 receptor CXCR3. In this study we have demonstrated that MC products released from granules soon after cell activation, or newly synthesized and then released later, differentially modulated levels of CXCL10 released by ASM cells from donors with and without asthma. Thus mast cells in the ASM have the potential to up- and downregulate chemokine levels locally and thereby affect their own recruitment and that of other inflammatory cells to the ASM in asthma.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors acknowledge the collaborative effort of the SSWAHS Theatre and Pathology Staff, Dr. M. Baraket and Associate Professor G. King (Woolcock Institute of Medical Research, Sydney), Professor I. Young (Royal Prince Alfred Hospital, Sydney), the Cardiopulmonary Transplant Team at St. Vincent’s Hospital, and their RRG colleagues who helped with lung sample/biopsy collection. This study was funded by project grants from the NHMRC of Australia.

References

[1] M. Saetta and G. Turato, “Airway pathology in asthma,” European Respiratory Journal, vol. 18, no. 34, pp. 188–23s, 2001.
[2] P. Bradding, A. F. Walls, and S. T. Holgate, “The role of the mast cell in the pathophysiology of asthma,” Journal of Allergy and Clinical Immunology, vol. 117, no. 6, pp. 1277–1284, 2006.
[3] J. Bousquet, P. K. Jeffery, W. W. Busse, M. Johnson, and A. M. Vignola, “Asthma: from bronchoconstriction to airways inflammation and remodeling,” The American Journal of Respiratory and Critical Care Medicine, vol. 161, no. 5, pp. 1720–1745, 2000.
[4] N. G. Carroll, S. Mutavdzic, and A. L. James, “Distribution and degranulation of airway mast cells in normal and asthmatic subjects,” European Respiratory Journal, vol. 19, no. 5, pp. 879–885, 2002.
[5] K. Amin, C. Janson, G. Boman, and P. Venge, “The extracellular deposition of mast cell products is increased in hypertrophic airways smooth muscles in allergic asthma but not in nonallergic asthma,” Allergy, vol. 60, no. 10, pp. 1241–1247, 2005.
[6] H. Begueret, P. Berger, J-M. Vernejoux, L. Dubuisson, R. Marthan, and J. M. Tunon-De-Lara, “Inflammation of bronchial smooth muscle in allergic asthma,” Thorax, vol. 62, no. 1, pp. 8–15, 2007.
[7] C. E. Brightling, P. Bradding, F. A. Symon, S. T. Holgate, A. J. Wardlaw, and I. D. Pavord, “Mast-cell infiltration of airway smooth muscle in asthma,” New England Journal of Medicine, vol. 346, no. 22, pp. 1699–1705, 2002.
[8] S. Balzar, M. L. Fajt, S. A. A. Comhair et al., “Mast cell phenotype, location, and activation in severe asthma: data from the Severe Asthma Research Program,” The American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 3, pp. 299–309, 2011.
[9] I. G. Reischl, W. R. Coward, and M. K. Church, “Molecular consequences of human mast cell activation following immunoglobulin E-high-affinity immunoglobulin E receptor (IgE-FcεRI) interaction,” Biochemical Pharmacology, vol. 58, no. 12, pp. 1841–1850, 1999.
[10] S. Page, A. J. Ammit, J. L. Black, and C. L. Armour, “Human mast cell and airway smooth muscle cell interactions: implications for asthma,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 281, no. 6, pp. L131–L1323, 2001.
[11] O. Ghaffar, Q. Hamid, P. M. Renzi et al., “Constitutive and cytokine-stimulated expression of eotaxin by human airway smooth muscle cells,” The American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 6, pp. 1933–1942, 1999.
[12] S. J. Hirst, M. P. Hallsworth, Q. Peng, and T. H. Lee, “Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1β and is mediated by the interleukin-4 receptor α-chain,” The American Journal of Respiratory and Critical Care Medicine, vol. 165, no. 8, pp. 1161–1171, 2002.
[13] L. Pang, M. Nie, L. Corbett, A. Sutcliffe, and A. J. Knox, “Mast cell β-tryptase selectively cleaves eotaxin and RANTES and abrogates their eosinophil chemotactic activities,” Journal of Immunology, vol. 176, no. 6, pp. 3788–3795, 2006.
[14] H. Alkhouri, F. Hollins, L. M. Moir, C. E. Brightling, C. L. Armour, and J. M. Hughes, “Human lung mast cells modulate the functions of airway smooth muscle cells in asthma,” Allergy, vol. 66, no. 9, pp. 1231–1241, 2011.
[15] J. Chhabra, Y. Z. Li, H. Alkhouri et al., “Histamine and tryptase modulate asthmatic airway smooth muscle GM-CSF and RANTES release,” European Respiratory Journal, vol. 29, no. 5, pp. 861–870, 2007.
[16] C. E. Brightling, D. Kaur, P. Berger, A. J. Morgan, A. J. Wardlaw, and P. Bradding, “Differential expression of CCR3 and CXCR3 by human lung and bone marrow-derived mast cells: implications for tissue mast cell migration,” Journal of Leukocyte Biology, vol. 77, no. 5, pp. 759–766, 2005.
[17] C. E. Brightling, A. J. Ammit, D. Kaur et al., “The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle,” The American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 10, pp. 1103–1108, 2005.
[18] Y. Alrashdan, H. Alkhouri, E. Chen et al., “Asthmatic airway smooth muscle CXCL10 production: mitogen-activated protein kinase JNK involvement,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 302, pp. L1118–L1127, 2012.

[19] M. B. Sukkar, A. J. Stanley, A. E. Blake et al., “Proliferative and ‘synthetic’ airway smooth muscle cells are overlapping populations,” Immunology and Cell Biology, vol. 82, no. 5, pp. 471–478, 2004.

[20] H. Marumoto, L. M. Moir, B. G. G. Oliver et al., “Comparison of gel contraction mediated by airway smooth muscle cells from patients with and without asthma,” Thorax, vol. 62, no. 10, pp. 848–854, 2007.

[21] L. M. Ruck, C. A. Rizzo, J. C. Anthes et al., “Synergistic antiallergic activity of combined histamine H1- and cysteinyl leukotriene-receptor blockade in human bronchus,” Life Sciences, vol. 68, no. 25, pp. 2825–2834, 2001.

[22] D. A. Knight, G. A. Stewart, and P. J. Thompson, “Histamine tachyphylaxis in human airway smooth muscle: the role of H1-receptors and the bronchial epithelium,” The American Review of Respiratory Disease, vol. 146, no. 1, pp. 137–140, 1992.

[23] P. Chomczynski and N. Sacchi, “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,” Analytical Biochemistry, vol. 162, no. 1, pp. 156–159, 1987.

[24] A. Sutcliffe, D. Kaur, S. Page et al., “Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics,” Thorax, vol. 61, no. 8, pp. 657–662, 2006.

[25] D. Ramos-Barbón, R. Fraga-Iriso, N. S. Brienza et al., “T cells localize with proliferating smooth muscle α-actin+ cell compartments in asthma,” The American Journal of Respiratory and Critical Care Medicine, vol. 182, no. 3, pp. 317–324, 2010.

[26] N. N. Jarjour, W. J. Calhoun, L. B. Schwartz, and W. W. Busse, “Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction,” The American Review of Respiratory Disease, vol. 144, no. 1, pp. 83–87, 1991.

[27] S. J. Hill, C. R. Ganellin, H. Timmerman et al., “International union of pharmacology. XIII. Classification of histamine receptors,” Pharmacological Reviews, vol. 49, no. 3, pp. 253–278, 1997.

[28] M. Dy and E. Schneider, “Histamine-cytokine connection in immunity and hematopoiesis,” Cytokine and Growth Factor Reviews, vol. 15, no. 5, pp. 393–410, 2004.

[29] R. A. Bakker, S. B. I. Schoonjus, J. Smit, H. Timmerman, and R. Leurs, “Histamine H, receptor activation of nuclear factor-kappaB: roles for Gbeta gamma- and Galphai/II-subunits in constitutive and agonist-mediated signalling,” Molecular Pharmacology, vol. 60, pp. 1133–1142, 2001.

[30] D. Zocci, J. P. McMorrow, and E. P. Murphy, “Histamine modulation of peripheral CRH receptor type 2 expression is dependent on Ca2+ signalling and NF-κB/p65 transcriptional activity,” Molecular Immunology, vol. 47, no. 7-8, pp. 1426–1437, 2010.

[31] K. Hegyi, A. Falus, and S. Toth, “Elevated CREB activity in embryonic fibroblasts of gene-targeted histamine deficient mice,” Inflammation Research, vol. 56, no. 8, pp. 339–344, 2007.

[32] E. L. Hardaker, A. M. Bacon, K. Carlson et al., “Regulation of TNF-alpha- and IFN-gamma-induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease,” The FASEB Journal, vol. 18, no. 1, pp. 191–193, 2004.

[33] N. Smith, C. A. Browning, N. Duroudier et al., “Salmeterol and cytokines modulate inositol-phosphate signalling in Human airway smooth muscle cells via regulation at the receptor locus,” Respiratory Research, vol. 8, article 68, 2007.

[34] D. L. Clarke, R. L. Cliford, S. Jindarat et al., “TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein,” Journal of Biological Chemistry, vol. 285, no. 38, pp. 29101–29110, 2010.

[35] X. Tan, Y. A. Alrashdan, H. Alkhouri, B. G. G. Oliver, C. I. Armour, and J. M. Hughes, “Airway smooth muscle CXCR3 ligand production: regulation by JAK-STAT1 and intracellular calcium,” The American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 304, pp. L790–L802, 2013.

[36] P. Seidel, H. Alkhouri, D. J. Lalor, J. K. Burgess, C. L. Armour, and J. M. Hughes, “Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies,” Respiratory Research, vol. 13, article 90, 2012.

[37] P. F. Delmotte, B. Yang, M. A. Thompson, C. M. Pabellick, Y. S. Prakash, and G. C. Sieck, “Inflammation alters regional mitochondrial calcium in human airway smooth muscle cells,” The American Journal of Physiology—Cell Physiology, vol. 303, pp. C244–C256, 2012.

[38] Y. Amrani, A. L. Lazar, R. Hoffman, K. Amin, S. Ousmer, and R. A. Panettieri Jr., “Activation of p55 tumor necrosis factor-α receptor-1 coupled to tumor necrosis factor receptor-associated factor 2 stimulates intercellular adhesion molecule-1 expression by modulating a thapsigargin-sensitive pathway in human tracheal smooth muscle cells,” Molecular Pharmacology, vol. 58, no. 1, pp. 237–245, 2000.

[39] N. Kanda and S. Watanabe, “Histamine enhances the production of granulocyte-macrophage colony-stimulating factor via protein kinase Ca and extracellular signal-regulated kinase in human keratinocytes,” Journal of Investigative Dermatology, vol. 122, no. 4, pp. 863–872, 2004.

[40] M. Ichinose and P. J. Barnes, “Inhibitory histamine H1-receptors on cholinergic nerves in human airways,” European Journal of Pharmacology, vol. 163, no. 2-3, pp. 1426–1437, 1989.

[41] F. Gantner, K. Sakai, M. W. Tusche, W. W. Cruikshank, D. M. Center, and K. B. Bacon, “Histamine H4 and H2 receptors control histamine-induced interleukin-16 release from human CD8+ T cells,” Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 1, pp. 300–307, 2002.

[42] C. A. Akdis, “Immune regulation by histamine H4 receptors in skin,” Journal of Investigative Dermatology, vol. 128, no. 7, pp. 1615–1616, 2008.

[43] H. D. Lim, R. M. Van Rijn, P. Ling, R. A. Bakker, R. L. Thurmond, and R. Leurs, “Evaluation of histamine H1-, H2-, and H4-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 3, pp. 1310–1321, 2005.

[44] G. Horvath, E. S. Mendes, N. Schmid et al., “The effect of corticosteroids on the disposal of long-acting β2-agonists by airway smooth muscle cells,” Journal of Allergy and Clinical Immunology, vol. 120, no. 5, pp. 1103–1109, 2007.

[45] D. Gründemann, G. Liebich, N. Kiefer, S. Köster, and E. Schömig, “Selective substrates for non-neuronal monoamine transporters,” Molecular Pharmacology, vol. 56, no. 1, pp. 1–10, 1999.
[46] R. Saunders, A. Sutcliffe, L. Woodman et al., “The airway smooth muscle CCR3/CCL11 axis is inhibited by mast cells,” Allergy, vol. 63, no. 9, pp. 1148–1155, 2008.

[47] F. Hollins, D. Kaur, W. Yang et al., “Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: cooperative roles for CADM1, stem cell factor, and IL-6,” Journal of Immunology, vol. 181, no. 4, pp. 2772–2780, 2008.

[48] Y. Ohkawara, K. Yamauchi, Y. Tanno et al., “Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering,” The American Journal of Respiratory Cell and Molecular Biology, vol. 7, no. 4, pp. 385–392, 1992.